- Conditions: Obesity; Overweight
Interventions: Drug: NB32; Drug: PBO; Behavioral: Weight Management Program
Sponsors: Orexigen Therapeutics, Inc; Orexigen Therapeutics, Inc
Not yet recruiting - verified May 2012 - Conditions: Type 2 Diabetes; Overweight; Obesity
Interventions: Behavioral: Weight Watchers modified program; Other: Standard Care group
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Weight Watchers International
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Proliferative Diabetic Retinopathy
Interventions: Drug: Macugen; Drug: Sham
Sponsors: Greater Houston Retina Research; Greater Houston Retina Research
Recruiting - verified April 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Conditions: Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Impaired Glucose Tolerance; Diabetes
Intervention: Drug: exenatide
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; Amylin Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Conditions: Diabetes Mellitus; Depression
Interventions: Behavioral: Healthy Outcomes through Patient Empowerment (HOPE); Behavioral: Enhanced Usual Care
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012 - Conditions: Type 2 Diabetes Mellitus; Renal Impairment
Interventions: Drug: LX4211; Drug: LX4211 Placebo
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone Methyl
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Glycemic Control
Interventions: Drug: TAK-875; Drug: Sitagliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified April 2012 - Condition: Diabetic Macular Edema
Interventions: Drug: 0.50mg ranibizumab; Procedure: Targeted Pan Retinal Photocoagulation
Sponsors: Greater Houston Retina Research; David M. Brown, M.D.; Genentech
Recruiting - verified March 2012 - Condition: Diabetic Neuropathy, Painful
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin; Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Diabetic Peripheral Neuropathy; Pain
Interventions: Drug: QUTENZA; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: PF-04937319 10 mg; Drug: PF-04937319 50 mg; Drug: PF-04937319 100 mg; Drug: Glimepiride
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Painful Diabetic Neuropathy
Interventions: Drug: SKL11197; Drug: Placebo
Sponsors: SK Life Science; SK Life Science
Recruiting - verified March 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin detemir; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin; Drug: linagliptin; Drug: linagliptin medium dose; Drug: metformin placebo; Drug: metformin placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Type 2 Diabetes Mellitus; Obesity
Interventions: Drug: Liraglutide; Drug: Saline
Sponsors: University of Texas Southwestern Medical Center; Ildiko Lingvay; Novo Nordisk
Recruiting - verified January 2012 - Conditions: Chronic Kidney Disease; Type 2 Diabetes
Interventions: Drug: 20 mg bardoxolone methyl; Drug: Placebo
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Conditions: Hypertension; Diabetes
Interventions: Drug: Placebo; Drug: Azilsartan medoxomil; Drug: Azilsartan medoxomil
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Device: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature; Device: Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
Sponsors: Medtronic Diabetes; Medtronic Diabetes
Recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - New formulation of insulin glargine; Drug: HOE 901 - Insulin glargine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Pharmacokinetics
Intervention: Drug: TAK-875 and Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: DS-5565 tablet; Drug: pregabalin capsule; Drug: Placebo
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012 - Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Interventions: Drug: CTP-499; Drug: Placebo
Sponsors: Concert Pharmaceuticals; Concert Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Diabetes Mellitus; Type 2 Diabetes
Interventions: Drug: Sitagliptin; Drug: Metformin; Drug: Placebo to sitagliptin; Drug: Placebo to metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Proliferative Diabetic Retinopathy
Interventions: Other: Prompt Panretinal Photocoagulation; Drug: 0.5-mg Ranibizumab; Other: Deferred panretinal photocoagulation
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); Genentech
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin Lispro; Drug: Insulin Aspart
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: Sitagliptin / Metformin; Drug: Placebo to Metformin; Drug: Placebo to Sitagliptin / Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine /lixisenatide fixed combination (HOE901/AVE0010); Drug: Insulin glargine (HOE901)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Comparator: Placebo; Biological: Insulin Glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.; Merck; Pfizer; Eli Lilly and Company; Takeda Global Research & Development Center, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis
Recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus
Intervention: Drug: AMG 151
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Conditions: Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 10mg TZP-102; Drug: 20mg TZP-102
Sponsors: Tranzyme, Inc.; Tranzyme, Inc.
Recruiting - verified April 2012 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Technosphere Insulin; Drug: Technosphere Inhalation Powder
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Technosphere Insulin with MedToneC Inhaler in combination with a basal insulin; Drug: Technosphere Insulin with Gen2C Inhaler in combination with a basal insulin; Drug: Insulin Aspart in combination with a basal insulin
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Diabetes Mellitus
Intervention: Drug: AMG 876
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Choroidal Neovascularization; Diabetic Retinopathy; Diabetic Macular Edema
Interventions: Drug: PF-04523655 (Stratum I); Drug: PF-04523655 and ranibizumab; Drug: ranibizumab; Drug: PF-04523655 (Stratum II)
Sponsors: Quark Pharmaceuticals; Quark Pharmaceuticals
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: PF-04937319 - 3mg; Drug: PF-04937319 - 20mg; Drug: PF-04937319 - 50mg; Drug: PF-04937319 - 100mg; Drug: Sitagliptin - 100mg
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Angina Pectoris; Coronary Artery Disease; Type 2 Diabetes Mellitus
Intervention: Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Lower Extremity Chronic Ulcers; Diabetes Mellitus
Interventions: Biological: Curexcell; Biological: Sham injection
Sponsors: Macrocure Ltd.; Macrocure Ltd.; Averion International Corporation
Recruiting - verified September 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2963016; Drug: Lantus; Drug: Oral Antihyperglycemic Medications (OAMs)
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetic Foot Ulcers; Diabetic Foot Wounds
Interventions: Biological: Santyl; Procedure: Standard Care
Sponsors: Healthpoint; Healthpoint
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: lisinopril; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Atrasentan; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Wounds; Diabetes Complications; Diabetic Foot; Foot Ulcer
Intervention: Other: Online Wound Electronic Medical Record
Sponsors: New York University School of Medicine; New York University School of Medicine; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012 - Conditions: Diabetes; Immunosuppression
Intervention: Procedure: Gastric emptying test
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; Novartis Pharmaceuticals
Recruiting - verified June 2011 - Conditions: Hypertension; Stage 2 Hypertension; Diabetes
Interventions: Drug: Valturna + amlodipine; Drug: valturna + placebo; Drug: Valturna + chlorthalidone
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Biological: albiglutide (GSK716155); Biological: albiglutide (GSK716155)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI1356 low dose; Drug: placebo; Drug: BI1356 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetic Retinopathy
Intervention: Behavioral: Diabetes Education
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Gestational Diabetes Mellitus
Interventions: Drug: Glyburide; Drug: Metformin; Drug: Glyburide-Metformin combination
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Washington; University of Pittsburgh; University of Texas; Indiana University School of Medicine; RTI International
Recruiting - verified January 2012 - Condition: Endocrine System Diseases
Interventions: Drug: Metformin; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012 - Conditions: Diabetes; Pre-Diabetes
Intervention: Drug: water-soluble cinnamon extract (Cinnulin PF)
Sponsors: Mike O'Callaghan Federal Hospital; Mike O'Callaghan Federal Hospital
Not yet recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathic Pain
Interventions: Drug: BMS-954561; Drug: Pregabalin; Drug: BMS-954561; Drug: Placebo matching BMS-954561; Drug: Placebo matching Pregabalin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetic Foot Ulcers
Interventions: Device: Epiflo; Other: Moist Wound Therapy
Sponsors: Ogenix Corporation; Ogenix Corporation
Recruiting - verified December 2011 - Condition: Type 1 Diabetes
Intervention: Drug: Leptin ( Metreleptin )
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Diabetic Nephropathy; Proteinuria; Oxidative Stress
Interventions: Drug: N-acetylcysteine placebo + silibin placebo; Drug: N-acetylcysteine active + silibin placebo; Drug: N-acetylcysteine placebo + silibin active; Drug: N-acetylcysteine active + silibin active; Drug: N-acetylcysteine active + high-dose silibin active
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Ankle Equinus; Ankle Contracture; Diabetes Mellitus
Interventions: Other: Standard of care; Device: Dynasplint
Sponsors: Dynasplint Systems, Inc.; Dynasplint Systems, Inc.
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin lispro; Drug: Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Procedure: Sleeve Gastrectomy and Ileal transposition; Dietary Supplement: dietary and medical management
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified February 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Pioglitazone 15 mg; Drug: Pioglitazone 45 mg; Drug: Pioglitazone 30 mg; Drug: BI 1356 / Pioglitazone 15 mg FDC; Drug: BI 1356; Drug: BI 1356 / Pioglitazone 30 mg FDC; Drug: BI 1356 / Pioglitazone 45 mg FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Diabetes, Obesity
Intervention: Behavioral: Tu Salud Si Cuenta Behavioral Intervention
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified February 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified August 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetic Foot Ulcers
Interventions: Drug: Santyl; Other: White Petrolatum
Sponsors: Healthpoint; Healthpoint
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: DiaPep277; Drug: Placebo
Sponsors: Andromeda Biotech Ltd.; Andromeda Biotech Ltd.
Recruiting - verified September 2011 - Condition: Diabetes Mellitus
Interventions: Drug: BGP-15 100 mg QD; Drug: BGP-15 100 mg BID; Drug: Placebo BID; Drug: BGP-15 200 mg QD; Drug: BGP-15 200 mg BID; Drug: BGP-15 400 mg QD
Sponsors: N-Gene Research Laboratories, Inc.; N-Gene Research Laboratories, Inc.; Integrium; Msource Medical Development GmbH; Kinexum LLC; Thermo Fisher Scientific; Haupt Pharma Wülfing GmbH; BARC nv
Recruiting - verified June 2011 - Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified August 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified February 2012 - Condition: Diabetic Gastroparesis
Intervention: Device: CGMS and insulin pump
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011 - Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: placebo; Drug: pioglitazone; Dietary Supplement: Vitamin E
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified February 2012 - Conditions: Chronic Periodontitis; Type 2 Diabetes
Interventions: Procedure: Non-surgical periodontal treatment; Other: Delayed non-surgical periodontal therapy
Sponsors: Stony Brook University; Stony Brook University; University of Alabama at Birmingham; University of Minnesota - Clinical and Translational Science Institute; The University of Texas Health Science Center, Houston; University of Texas; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified December 2011 - Conditions: Vitreous Hemorrhage; Proliferative Diabetic Retinopathy
Interventions: Drug: Ranibizumab; Behavioral: Saline
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified February 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide; Drug: insulin lispro
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified January 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Rilonacept
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified December 2010 - Conditions: Malignant Neoplasm Overlapping Lip Site; Mouth Neoplasms; Malignant Neoplasm of Other and Ill-defined Sites in the Lip, Oral Cavity and Pharynx; Leukoplakia; Other Lesions of Oral Mucosa; Pigmented Oral Mucosal Lesion; Unspecified Lesions of Oral Mucosa; Oral Lichenoid Lesions; Premalignant Lesion; Other and Unspecified Lesions of Oral Mucosa; Granuloma and Granuloma-like Lesions of Oral Mucosa; Diseases of the Oral Soft Tissue, Excluding Lesions Specific for Gingiva and Tongue; Oral Premalignant Lesion; Oral Premalignant Neoplasms; Oral Leukoplakia
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Minnesota - Clinical and Translational Science Institute; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; University of Alabama at Birmingham; University of Iowa; University of Maryland; Roswell Park Cancer Institute; Columbia University; Weill Medical College of Cornell University; European Institute of Oncology
Recruiting - verified April 2012 - Condition: Diabetic Foot Ulcer
Interventions: Drug: HO/03/03 10µg; Drug: Placebo
Sponsors: HealOr; HealOr; Clinigene International Ltd; Cato Research
Recruiting - verified December 2011 - Conditions: Diabetic Nephropathies; Proteinuria; Oxidative Stress
Interventions: Dietary Supplement: N-acetylcysteine; Dietary Supplement: silibin; Dietary Supplement: high-dose silibin; Dietary Supplement: N-acetylcysteine placebo; Dietary Supplement: silibin placebo
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Center for Complementary and Alternative Medicine (NCCAM); Department of Veterans Affairs
Recruiting - verified August 2011 - Conditions: Obesity; Type 2 Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; National Institutes of Health (NIH)
Recruiting - verified August 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012 - Conditions: Obesity; Diabetes
Interventions: Behavioral: TSSC; Behavioral: TSSC Randomized Behavioral Intervention for weight loss
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified February 2012 - Conditions: Diabetic Foot; Leg Ulcer; Decubitus Ulcer
Intervention:
Sponsors: Southwest Regional Wound Care Center; Southwest Regional Wound Care Center
Recruiting - verified March 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2011 - Condition: Painful Diabetic Neuropathy
Intervention: Procedure: Nerve Decompression
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified August 2011 - Condition: Type 2 Diabetes
Interventions: Drug: placebo; Drug: exenatide; Drug: exenatide
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified August 2011 - Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Conditions: Islet Cell Transplantation; Type 1 Diabetes
Intervention: Drug: Islet cell transplantation
Sponsors: Baylor Research Institute; Baylor Research Institute; Baylor Health Care System
Recruiting - verified February 2012 - Condition: Endometrial Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Insulin Resistance; Hypertriglyceridemia; Diabetes; Hepatic Steatosis
Intervention: Other: low-fat diet ( Still recruiting )
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; National Institutes of Health (NIH); Takeda Global Research & Development Center, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011


